FDMT
NASDAQ4D Molecular Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks57-70%
2025-10-262026-04-19
Mix2390d
- Other13(57%)
- SEC Filings5(22%)
- Insider4(17%)
- Analyst1(4%)
Latest news
25 items- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 14, 2026, the compensation committee of the Company's board of directors granted five new non-executive employees 67,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into em
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- INSIDERSEC Form 4 filed by Simms Christopher Paul4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Kirn David4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Bizily Scott4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- INSIDERSEC Form 4 filed by Gupta Ashoo4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- SECSEC Form S-8 filed by 4D Molecular Therapeutics Inc.S-8 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SECSEC Form 10-K filed by 4D Molecular Therapeutics Inc.10-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- PR4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesCompleted enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and SPECTRA DME trial 2-year data in H2 20264D-150 DME global Phase 3 trial initiation expected in Q3 2026$514 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and dis
- PR4DMT to Participate in Upcoming Investor MeetingsEMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March. Leerink Partners Mountain Meeting Event Date:March 22-25, 2026 RBC Capital Markets Global Ophthalmology ConferencePresentation Date:Tuesday, March 24, 2026Presentation Time:3:45 p.m. GMT An archived copy of the webcast will be available for up to one year on th
- PR4DMT to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March. TD Cowen 46th Annual Health Care Conference Presentation Date:Tuesday, March 3, 2026Presentation Time:10:30 a.m. ETWebcast Link:Webcast Leerink Global Healthcare Conference Presentation Date:Tuesday, March 10, 2026Presentation Time:4:20 p.m. ETWebcast Link:Webca
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- SECSEC Form SCHEDULE 13G filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on February 10, 2026, the compensation committee of the Company's board of directors granted nine new non-executive employees 124,200 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- PR4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMDEnrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients Topline data from 4FRONT-1 expected in H1 20274FRONT-2 global site activation momentum continues, with enrollment completion on track for H2 2026 and topline data expected in H2 2027 EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT, or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pote
- ANALYSTBarclays resumed coverage on 4D Molecular Therapeutics with a new price targetBarclays resumed coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $33.00
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company's board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Mark
- INSIDERSEC Form 4 filed by Director Sblendorio Glenn4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)